In pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL), KRAS is mutated in approximately 44% of cases and is linked to relapse as well as chemotherapy resistance [9]. Here, KRAS is linked to acute lymphoblastic leukemia.